Clivatuzumab-based blood test diagnostic data

Data from >600 blood samples from patients with various forms of pancreatic cancer, cancers of the surrounding organs, benign pancreatic disease and healthy volunteers showed that Immunomedics' clivatuzumab-based blood test had 76% sensitivity for detecting pancreatic ductal adenocarcinoma. When combined with the CA19-9 tumor marker, the sensitivity of the assay increased to 85%. Additionally, the clivatuzumab-based blood test had sensitivities of 64%, 50% and 48% for detecting stage I pancreatic cancer, extrahepatic biliary adenocarcinoma and periampullary adenocarcinoma, respectively. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium in San Francisco. ...